Loading...
•
Jun 30, 2024
Applied Therapeutics Q2 2024 Earnings Report
Applied Therapeutics reported financial results for the second quarter ended June 30, 2024.
Key Takeaways
Applied Therapeutics reported a net income of $2.9 million for the second quarter of 2024, a significant improvement compared to a net loss of $29.6 million for the same period in 2023. The company is progressing with regulatory submissions for govorestat in Classic Galactosemia and SORD Deficiency.
Net income for Q2 2024 was $2.9 million, or $0.02 per basic common share.
Net loss of $0.13 per diluted common share for Q2 2024.
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review.
Company aligned with the Neurology I Division on plans to submit an NDA under Accelerated Approval for govorestat for the treatment of SORD Deficiency; Expect to submit an NDA in early Q1 2025.
Applied Therapeutics
Applied Therapeutics
Forward Guidance
The press release contains forward-looking statements that involve substantial risks and uncertainties.